Prostate cancer (PCa) is the most commonly diagnosed malignancy in men worldwide. Accurate triage of patients based on tumor aggressiveness and staging is critical for selecting appropriate management pathways. While magnetic resonance imaging (MRI) has become a mainstay in PCa diagnosis, most predictive models rely on multiparametric imaging or invasive inputs, limiting generalizability in real-world clinical settings. This study aimed to develop and validate machine learning (ML) models using radiomic features extracted from T2-weighted MRI--alone and in combination with clinical variables--to predict ISUP grade (tumor aggressiveness), lymph node involvement (cN) and distant metastasis (cM). A retrospective multicenter cohort from three European sites in the Chaimeleon project was analyzed. Radiomic features were extracted from prostate zone segmentations and lesion masks, following standardized preprocessing and ComBat harmonization. Feature selection and model optimization were performed using nested cross-validation and Bayesian tuning. Hybrid models were trained using XGBoost and interpreted with SHAP values. The ISUP model achieved an AUC of 0.66, while the cN and cM models reached AUCs of 0.77 and 0.80, respectively. The best-performing models consistently combined prostate zone radiomics with clinical features such as PSA, PIRADSv2 and ISUP grade. SHAP analysis confirmed the importance of both clinical and texture-based radiomic features, with entropy and non-uniformity measures playing central roles in all tasks. Our results demonstrate the feasibility of using T2-weighted MRI and zonal radiomics for robust prediction of aggressiveness, nodal involvement and distant metastasis in PCa. This fully automated pipeline offers an interpretable, accessible and clinically translatable tool for first-line PCa triage, with potential integration into real-world diagnostic workflows.

Heterogeneity is a fundamental characteristic of brain diseases, distinguished by variability not only in brain atrophy but also in the complexity of neural connectivity and brain networks. However, existing data-driven methods fail to provide a comprehensive analysis of brain heterogeneity. Recently, dynamic neural networks (DNNs) have shown significant advantages in capturing sample-wise heterogeneity. Therefore, in this article, we first propose a novel dynamic heterogeneity-aware network (DHANet) to identify critical heterogeneous brain regions, explore heterogeneous connectivity between them, and construct a heterogeneous-aware structural brain network (HGA-SBN) using structural magnetic resonance imaging (sMRI). Specifically, we develop a 3-D dynamic convmixer to extract abundant heterogeneous features from sMRI first. Subsequently, the critical brain atrophy regions are identified by dynamic prototype learning with embedding the hierarchical brain semantic structure. Finally, we employ a joint dynamic edge-correlation (JDE) modeling approach to construct the heterogeneous connectivity between these regions and analyze the HGA-SBN. To evaluate the effectiveness of the DHANet, we conduct elaborate experiments on three public datasets and the method achieves state-of-the-art (SOTA) performance on two classification tasks.

Current brain tumor segmentation methods often utilize a U-Net architecture based on efficient convolutional neural networks. While effective, these architectures primarily model local dependencies, lacking the ability to capture global interactions like pure Transformer. However, using pure Transformer directly causes the network to lose local feature information. To address this limitation, we propose the Generative Adversarial Dilated Attention Convolutional Transformer(GDacFormer). GDacFormer enhances interactions between tumor regions while balancing global and local information through the integration of adversarial learning with an improved transformer module. Specifically, GDacFormer leverages a generative adversarial segmentation network to learn richer and more detailed features. It integrates a novel Transformer module, DacFormer, featuring multi-scale dilated attention and a next convolution block. This module, embedded within the generator, aggregates semantic multi-scale information, efficiently reduces the redundancy in the self-attention mechanism, and enhances local feature representations, thus refining the brain tumor segmentation results. GDacFormer achieves Dice values for whole tumor, core tumor, and enhancing tumor segmentation of 90.9%/90.8%/93.7%, 84.6%/85.7%/93.5%, and 77.9%/79.3%/86.3% on BraTS2019-2021 datasets. Extensive evaluations demonstrate the effectiveness and competitiveness of GDacFormer. The code for GDacFormer will be made publicly available at https://github.com/MuqinZ/GDacFormer.

Friedreich ataxia (FRDA) is a rare, inherited progressive movement disorder for which there is currently no cure. The field urgently requires more sensitive, objective, and clinically relevant biomarkers to enhance the evaluation of treatment efficacy in clinical trials and to speed up the process of drug discovery. This study pioneers the development of clinically relevant, multidomain, fully objective composite biomarkers of disease severity and progression, using multimodal neuroimaging and background data (i.e., demographic, disease history, genetics). Data from 31 individuals with FRDA and 31 controls from a longitudinal multimodal natural history study IMAGE-FRDA, were included. Using an elasticnet predictive machine learning (ML) regression model, we derived a weighted combination of background, structural MRI, diffusion MRI, and quantitative susceptibility imaging (QSM) measures that predicted Friedreich ataxia rating scale (FARS) with high accuracy (R² = 0.79, root mean square error (RMSE) = 13.19). This composite also exhibited strong sensitivity to disease progression over two years (Cohen's d = 1.12), outperforming the sensitivity of the FARS score alone (d = 0.88). The approach was validated using the Scale for the assessment and rating of ataxia (SARA), demonstrating the potential and robustness of ML-derived composites to surpass individual biomarkers and act as complementary or surrogate markers of disease severity and progression. However, further validation, refinement, and the integration of additional data modalities will open up new opportunities for translating these biomarkers into clinical practice and clinical trials for FRDA, as well as other rare neurodegenerative diseases.

Desmoid tumors are rare, locally invasive soft-tissue tumors with unpredictable clinical behavior. Imaging plays a crucial role in their diagnosis, measurement of disease burden, and assessment of treatment response. However, desmoid tumors' unique imaging features present challenges to conventional imaging metrics. The heterogeneous nature of these tumors, with a variable composition (fibrous, myxoid, or cellular), complicates accurate delineation of tumor boundaries and volumetric assessment. Furthermore, desmoid tumors can demonstrate prolonged stability or spontaneous regression, and biologic quiescence is often manifested by collagenization rather than bulk size reduction, making traditional size-based response criteria, such as Response Evaluation Criteria in Solid Tumors (RECIST), suboptimal. To overcome these limitations, advanced imaging techniques offer promising opportunities. Functional and parametric imaging methods, such as diffusion-weighted MRI, dynamic contrast-enhanced MRI, and T2 relaxometry, can provide insights into tumor cellularity and maturation. Radiomics and artificial intelligence approaches may enhance quantitative analysis by extracting and correlating complex imaging features with biological behavior. Moreover, imaging biomarkers could facilitate earlier detection of treatment efficacy or resistance, enabling tailored therapy. By integrating advanced imaging into clinical practice, it may be possible to refine the evaluation of disease burden and treatment response, ultimately improving the management and outcomes of patients with desmoid tumors.

The precise and timely diagnosis of brain tumors is essential for accelerating patient recovery and preserving lives. Brain tumors exhibit a variety of sizes, shapes, and visual characteristics, requiring individualized treatment strategies for each patient. Radiologists require considerable proficiency to manually detect brain malignancies. However, tumor recognition remains inefficient, imprecise, and labor-intensive in manual procedures, underscoring the need for automated methods. This study introduces an effective approach for identifying brain lesions in magnetic resonance imaging (MRI) images, minimizing dependence on manual intervention. The proposed method improves image clarity by combining guided filtering techniques with anisotropic Gaussian side windows (AGSW). A morphological analysis is conducted prior to segmentation to exclude non-tumor regions from the enhanced MRI images. Deep neural networks segment the images, extracting high-quality regions of interest (ROIs) and multiscale features. Identifying salient elements is essential and is accomplished through an attention module that isolates distinctive features while eliminating irrelevant information. An ensemble model is employed to classify brain tumors into different categories. The proposed technique achieves an overall accuracy of 99.94% and 99.67% on the publicly available brain tumor datasets BraTS2020 and Figshare, respectively. Furthermore, it surpasses existing technologies in terms of automation and robustness, thereby enhancing the entire diagnostic process.

The brain is a highly complex organ that manages many important tasks, including movement, memory and thinking. Brain-related conditions, like tumors and degenerative disorders, can be hard to diagnose and treat. Magnetic Resonance Imaging (MRI) serves as a key tool for identifying these conditions, offering high-resolution images of brain structures. Despite this, interpreting MRI scans can be complicated. This study tackles this challenge by conducting a comparative analysis of Vision Transformer (ViT) and Transfer Learning (TL) models such as VGG16, VGG19, Resnet50V2, MobilenetV2 for classifying brain diseases using MRI data from Bangladesh based dataset. ViT, known for their ability to capture global relationships in images, are particularly effective for medical imaging tasks. Transfer learning helps to mitigate data constraints by fine-tuning pre-trained models. Furthermore, Explainable AI (XAI) methods such as GradCAM, GradCAM++, LayerCAM, ScoreCAM, and Faster-ScoreCAM are employed to interpret model predictions. The results demonstrate that ViT surpasses transfer learning models, achieving a classification accuracy of 94.39%. The integration of XAI methods enhances model transparency, offering crucial insights to aid medical professionals in diagnosing brain diseases with greater precision.

PurposeTo develop a segmentation and quality control pipeline for short-axis cardiac magnetic resonance (CMR) cine images from the prospective, multi-center German National Cohort (NAKO). Materials and MethodsA deep learning model for semantic segmentation, based on the nnU-Net architecture, was applied to full-cycle short-axis cine images from 29,908 baseline participants. The primary objective was to determine data on structure and function for both ventricles (LV, RV), including end diastolic volumes (EDV), end systolic volumes (ESV), and LV myocardial mass. Quality control measures included a visual assessment of outliers in morphofunctional parameters, inter- and intra-ventricular phase differences, and LV time-volume curves (TVC). These were adjudicated using a five-point rating scale, ranging from five (excellent) to one (non-diagnostic), with ratings of three or lower subject to exclusion. The predictive value of outlier criteria for inclusion and exclusion was analyzed using receiver operating characteristics. ResultsThe segmentation model generated complete data for 29,609 participants (incomplete in 1.0%) and 5,082 cases (17.0 %) were visually assessed. Quality assurance yielded a sample of 26,899 participants with excellent or good quality (89.9%; exclusion of 1,875 participants due to image quality issues and 835 cases due to segmentation quality issues). TVC was the strongest single discriminator between included and excluded participants (AUC: 0.684). Of the two-category combinations, the pairing of TVC and phases provided the greatest improvement over TVC alone (AUC difference: 0.044; p<0.001). The best performance was observed when all three categories were combined (AUC: 0.748). Extending the quality-controlled sample to include acceptable quality ratings, a total of 28,413 (95.0%) participants were available. ConclusionThe implemented pipeline facilitated the automated segmentation of an extensive CMR dataset, integrating quality control measures. This methodology ensures that ensuing quantitative analyses are conducted with a diminished risk of bias.

To develop an interpretable machine learning (ML) model based on cardiac magnetic resonance (CMR) multimodal parameters and clinical data to discriminate Takotsubo syndrome (TTS), acute myocardial infarction (AMI), and acute myocarditis (AM), and to further assess the diagnostic value of right ventricular (RV) strain in TTS. This study analyzed CMR and clinical data of 130 patients from three centers. Key features were selected using least absolute shrinkage and selection operator regression and random forest. Data were split into a training cohort and an internal testing cohort (ITC) in the ratio 7:3, with overfitting avoided using leave-one-out cross-validation and bootstrap methods. Nine ML models were evaluated using standard performance metrics, with Shapley additive explanations (SHAP) analysis used for model interpretation. A total of 11 key features were identified. The extreme gradient boosting model showed the best performance, with an area under the curve (AUC) value of 0.94 (95% CI: 0.85-0.97) in the ITC. Right ventricular basal circumferential strain (RVCS-basal) was the most important feature for identifying TTS. Its absolute value was significantly higher in TTS patients than in AMI and AM patients (-9.93%, -5.21%, and -6.18%, respectively, p < 0.001), with values above -6.55% contributing to a diagnosis of TTS. This study developed an interpretable ternary classification ML model for identifying TTS and used SHAP analysis to elucidate the significant value of RVCS-basal in TTS diagnosis. An online calculator (https://lsszxyy.shinyapps.io/XGboost/) based on this model was developed to provide immediate decision support for clinical use.

We propose a novel framework for integrating fragmented multi-modal data in Alzheimer's disease (AD) research using large language models (LLMs) and knowledge graphs. While traditional multimodal analysis requires matched patient IDs across datasets, our approach demonstrates population-level integration of MRI, gene expression, biomarkers, EEG, and clinical indicators from independent cohorts. Statistical analysis identified significant features in each modality, which were connected as nodes in a knowledge graph. LLMs then analyzed the graph to extract potential correlations and generate hypotheses in natural language. This approach revealed several novel relationships, including a potential pathway linking metabolic risk factors to tau protein abnormalities via neuroinflammation (r>0.6, p<0.001), and unexpected correlations between frontal EEG channels and specific gene expression profiles (r=0.42-0.58, p<0.01). Cross-validation with independent datasets confirmed the robustness of major findings, with consistent effect sizes across cohorts (variance <15%). The reproducibility of these findings was further supported by expert review (Cohen's k=0.82) and computational validation. Our framework enables cross modal integration at a conceptual level without requiring patient ID matching, offering new possibilities for understanding AD pathology through fragmented data reuse and generating testable hypotheses for future research.